Regulatory News:
VEXIM (Paris:ALVXM) (FR0011072602 ‐ ALVXM / PEA-PME eligible), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announced its preliminary financial agenda for 2015.
ANNOUNCEMENT | DATE * | |
2014 Full-Year Sales | Monday, January 26, 2015 | |
2014 Full-Year Results | Tuesday, March 24, 2015 | |
Q1 2015 Sales | Thursday, April 16, 2015 | |
Annual General Meeting | Tuesday, May 19, 2015 | |
2015 Half-Year Sales | Monday, July 20, 2015 | |
2015 Half-Year Results | Wednesday, September 30, 2015 | |
Q3 2015 Sales | Tuesday, November 3, 2015 | |
Financial year ended December 31 |
* Subject to modification. Press releases are distributed after the financial markets closure.
About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from Bpifrance public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 59 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Panama, Venezuela, Chile, and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil and Peru. VEXIM has been listed on Alternext Paris since May 2012.
For further information, please go to www.vexim.com
SpineJack®1 implant for treating Vertebral
Compression Fractures
An important advantage of SpineJack® lies
in its ability to restore a fractured vertebra to its original shape,
restore the spinal column’s optimal anatomy and thus remove pain and
enable the patient to recover their functional capabilities. Specialized
instruments and guided by X-ray allow the implants into the vertebra to
be carried out by mini-invasive surgery in approximately 30 minutes
enabling the patient to be discharged shortly after surgery. The
SpineJack® range consists of three titanium implants with three
different diameters, thus covering 95% of vertebral compression
fractures and all patient morphologies. SpineJack® technology benefits
from the support of international scientific experts in the field of
spine surgery and worldwide patent protection until 2029. SpineJack® is
an investigational device in the United States and is not available for
U.S. sale.
- Name: VEXIM
- ISIN code: FR0011072602
- Ticker: ALVXM
- Member of the EnterNext© PEA-PME 150 index
1 This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.